Great Point Partners LLC Prothena Corp Public LTD CO Transaction History

Great Point Partners LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$11.0 - $28.24 $10.8 Million - $27.6 Million	-977,647 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$10.12 - $13.94 $5.78 Million - $7.96 Million	-570,832 Reduced 36.86%	977,647 $11.7 Million
Q3 2020 Nov 16, 2020	SELL	$9.93 - $13.47 $5.31 Million - $7.2 Million	-534,362 Reduced 25.66%	1,548,479 $15.5 Million
Q1 2020 May 15, 2020	SELL	$7.54 - $15.77 $136,474 - $285,437	-18,100 Reduced 0.86%	2,082,841 $22.3 Million
Q4 2019 Feb 14, 2020	BUY	$7.48 - $17.01 $261,052 - $593,649	34,900 Added 1.69%	2,100,941 $33.3 Million
Q3 2019 Nov 15, 2019	BUY	$6.89 - $10.45 $2.69 Million - $4.07 Million	389,791 Added 23.25%	2,066,041 $16.2 Million
Q2 2019 Aug 14, 2019	BUY	$8.85 - $12.49 $14.8 Million - $20.9 Million	1,676,250 New	1,676,250 $0

186

42.8M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $726M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Great Point Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Great Point Partners LLC with notifications on news.